With decades of hands-on experience, Sharp’s industry experts reveal their top five recommendations for a timely and ...
Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...
Though the FDA will continue its core activities, the agency will no longer be accepting NDAs and BLAs until the ...
During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is ...
Though unexpected CRLs issued by the FDA have caused ripples in the industry, Becky Wood believes that these cases are the ...
Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...
The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback